Report of Foreign Issuer (6-k)
May 26 2020 - 8:46AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2020
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934:
On May 26, 2020, the registrant issued the press release which is filed as
Exhibit
1 to this Report on Form 6-K.
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
BioLineRx Ltd.
|
|
|
|
|
|
|
By:
|
/s/ Philip Serlin
|
|
|
|
Philip Serlin
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024